Zhang Y. and coauthors hypothesized that dual inhibition of HDAC6 and PAK1 could have strong implications for tumor treatment by simultaneously targeting oncogenic metabolic pathways and epigenetic modification [164]. The gene discussed is HDAC6; the disease is neoplasm.